

Approval Date	Product	Company	Nanoparticle material	Drug	Indication
2019 (EU)	Hensify (NBTXR3)	Nanobiotix	Hafnium oxide nanoparticle		Locally-advanced soft tissue sarcoma (STS)
2017	Vyxeos	Celator/Jazz Pharma	Liposome	<u>Cytarabine/ Daunorubicin</u>	Acute myeloid leukemia
2015	Onivyde	Merrimack Pharma	Liposome	<u>Irinotecan</u>	Pancreatic cancer
2012	Marqibo	Talon	Liposome	<u>Vincristine</u>	Acute lymphoid leukemia
2010 (EU)	NanoTherm	Magforce Nanotechnologies	Iron oxide nanoparticle		Glioblastoma
2009 (EU)	Mepact	Takeda	Liposome	<u>Mifamurtide MTP-PE</u>	Osteosarcoma
2007 (South Korea)	Genexol-PM	Samyang/Biopharm	PEG-PLA polymeric micelle	<u>Paclitaxel</u>	Breast cancer, Lung cancer, Ovarian cancer
2006	Oncaspar	Enzon-Sigma-tau	Polymer protein conjugate	<u>L-asparaginase</u>	Leukemia
2005	Abraxane	Abraxis/Celgene	Nanoparticle-bound albumin	<u>Paclitaxel</u>	Breast cancer, Pancreatic cancer, Non-small-cell lung cancer
2000 (EU)	Myocet	Cephalon	Liposome	<u>Doxorubicin</u>	Breast Cancer
1999	DepoCyt	Pacira	Liposome	<u>Cytarabine</u>	Neoplastic meningitis
1998 (Taiwan)	Lipo-Dox	Taiwan Liposome	Liposome	<u>Doxorubicin</u>	Kaposi's sarcoma, Breast cancer, Ovarian cancer
1996	DaunoXome	Galen	Liposome	<u>Daunorubicin</u>	Kaposi's sarcoma
1995 1999 2003 2007 (Europe, Canada)	Doxil	Johnson and Johnson	Liposome	<u>Doxorubicin</u>	Kaposi's sarcoma, Ovarian cancer, Breast cancer, Multiple myeloma